Cyclerion Therapeutics Inc (CYCN)

$3.37

+0.32

(+10.51%)

Market is closed - opens 7 PM, 15 Apr 2024

Insights on Cyclerion Therapeutics Inc

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 47.7% return, outperforming this stock by 89.6%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 253.0% return, outperforming this stock by 346.9%

Performance

  • $3.00
    $3.55
    $3.37
    downward going graph

    10.98%

    Downside

    Day's Volatility :15.43%

    Upside

    5.0%

    downward going graph
  • $1.75
    $7.00
    $3.37
    downward going graph

    48.07%

    Downside

    52 Weeks Volatility :75.0%

    Upside

    51.86%

    downward going graph

Returns

PeriodCyclerion Therapeutics IncIndex (Russel 2000)
3 Months
-12.01%
0.0%
6 Months
-0.88%
0.0%
1 Year
-41.9%
-0.7%
3 Years
-93.87%
-21.3%

Highlights

Market Capitalization
8.2M
Book Value
$4.56
Earnings Per Share (EPS)
-5.39
Wall Street Target Price
4.0
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-38.34%
Return On Equity TTM
-115.85%
Revenue TTM
1.3M
Revenue Per Share TTM
0.59
Quarterly Revenue Growth YOY
14.099999999999998%
Gross Profit TTM
-29.7M
EBITDA
-9.6M
Diluted Eps TTM
-5.39
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
0.0
EPS Estimate Next Year
0.0
EPS Estimate Current Quarter
0.0
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Buy
    85%Buy
    14%Hold
    0
    0%Sell
Based on 7 Wall street analysts offering stock ratings for Cyclerion Therapeutics Inc(by analysts ranked 0 to 5 stars)
Based on 7 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
6
6
6
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 18.69%

Current $3.37
Target $4.00

Technicals Summary

Sell

Neutral

Buy

Cyclerion Therapeutics Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Cyclerion Therapeutics Inc
Cyclerion Therapeutics Inc
0.3%
-0.88%
-41.9%
-93.87%
-99.04%
Moderna, Inc.
Moderna, Inc.
1.62%
14.36%
-33.07%
-34.3%
306.89%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-5.67%
7.24%
9.09%
88.02%
140.93%
Novo Nordisk A/s
Novo Nordisk A/s
-7.48%
23.09%
47.7%
252.97%
394.48%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-2.99%
6.03%
18.9%
82.63%
117.3%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Cyclerion Therapeutics Inc
Cyclerion Therapeutics Inc
NA
NA
NA
0.0
-1.16
-0.38
NA
4.56
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.2
-0.29
-0.12
NA
36.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
26.28
26.28
1.51
44.87
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
46.32
46.32
2.38
3.35
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.64
28.64
0.54
16.78
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Cyclerion Therapeutics Inc
Cyclerion Therapeutics Inc
Buy
$8.2M
-99.04%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$41.0B
306.89%
24.73
-68.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$100.2B
140.93%
26.28
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$565.1B
394.48%
46.32
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$102.8B
117.3%
28.64
36.68%

Institutional Holdings

  • Slate Path Capital LP

    13.21%
  • MFN Partners Management, LP

    6.25%
  • TYNDALL CAPITAL PARTNERS L P

    6.07%
  • Tyndall Management, LLC

    6.07%
  • FMR Inc

    6.01%
  • Artal Group S A

    5.13%

Company Information

cyclerion therapeutics, inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of various treatments for serious and orphan diseases. its product candidates include olinciguat, an orally administered vascular soluble guanylate cyclase (sgc) stimulator that is in phase ii studies for the treatment of sickle cell disease (scd); praliciguat, an orally administered systemic sgc stimulator that is in phase ii trials for the treatment of diabetic nephropathy and heart failure with preserved ejection fraction; and iw-6463, an orally administered central nervous system (cns)-penetrant sgc stimulator, which is in phase i trials for neurodegenerative diseases. the company is also discovering liver-targeted sgc and lung-targeted sgc stimulators. cyclerion therapeutics, inc. was incorporated in 2018 and is headquartered in cambridge, massachusetts.

Organization
Cyclerion Therapeutics Inc
Employees
1
CEO
Dr. Regina Graul Ph.D.
Industry
Pharmaceuticals: Major

FAQs